You are here:

botulinum toxin type A (Xeomin®)

Advice

following an abbreviated submission

botulinum toxin type A (Xeomin®) is accepted for use within NHS Scotland.

Indication under review: post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.

In patients for whom botulinum toxin, type A is an appropriate choice of therapy, this offers an alternative formulation to the comparator product containing conventional botulinum toxin, type A complex.

Drug Details

Drug Name: botulinum toxin type A (Xeomin®)
SMC Drug ID: 731/11
Manufacturer: Merz Pharma UK Ltd
Indication: Post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 10 October 2011

Extra Notes

The marketing authorisation for botulinum toxin type A (Xeomin) was amended to cover spasticity of the upper limbs (i.e. no longer limited to use post stroke),  in November 2017. This minor licence change will not be assessed.

Back